

NIHB Recent Listings – January 2018

Drug	Listing Status	Criteria	Listing Date
<p>Metobject (methotrexate pre-filled syringes)</p>	<p>Open benefit</p>	<p>Effective January 10, 2018 Metobject (brand name of methotrexate pre-filled syringes) were listed as open benefits in the following strengths:</p> <ul style="list-style-type: none"> • Metobject Subcutaneous 25 mg/0.5 mL syringe • Metobject Subcutaneous 22.5 mg/0.45 mL syringe • Metobject Subcutaneous 20 mg/0.4 mL syringe • Metobject Subcutaneous 17.5 mg/0.35 mL syringe • Metobject Subcutaneous 15 mg/0.3 mL syringe • Metobject Subcutaneous 12.5 mg/0.25 mL syringe • Metobject Subcutaneous 10 mg/0.2 mL syringe • Metobject Subcutaneous 7.5 mg/0.15 mL syringe • Metobject 7.5 mg/0.75 mL syringe • Metobject 10 mg/mL syringe • Metobject 15 mg/1.5 mL syringe <p>This change is intended to add another pre-filled methotrexate syringe to the NIHB Drug Benefit List (DBL).</p>	<p>January 10, 2018</p>